HSD17B10 and acute kidney injury: To assess its specificity as a biomarker of CAMR, we measured its expression in PBMC from patients with acute rejection (AR, n = 9), patients with renal failure exhibiting deteriorating kidney function for non-immunological causes without renal transplantation (RF, n = 10) and healthy volunteers (HV, n = 8) (Figure 2B).